Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.

  title={Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.},
  author={Yifei Zhong and Edward Y. Chen and Ruijie Liu and Peter Y. Chuang and Sandeep K. Mallipattu and Christopher M. Tan and Neil R. Clark and Yueyi Deng and Paul E. Klotman and Avi Ma’ayan and John Cijiang He},
  journal={Journal of the American Society of Nephrology : JASN},
  volume={24 5},
  • Yifei Zhong, E. Chen, J. He
  • Published 4 April 2013
  • Biology
  • Journal of the American Society of Nephrology : JASN
The Connectivity Map database contains microarray signatures of gene expression derived from approximately 6000 experiments that examined the effects of approximately 1300 single drugs on several human cancer cell lines. We used these data to prioritize pairs of drugs expected to reverse the changes in gene expression observed in the kidneys of a mouse model of HIV-associated nephropathy (Tg26 mice). We predicted that the combination of an angiotensin-converting enzyme (ACE) inhibitor and a… 

Figures and Tables from this paper

Podocyte histone deacetylase activity regulates murine and human glomerular diseases
Results strongly suggest that inhibition of HDAC1 and HDAC2 activities may suppress the progression of human proteinuric kidney diseases through the regulation of EGR1.
Treatment of chronic kidney diseases with histone deacetylase inhibitors
Recent advances on the treatment of various chronic kidney diseases with HDACis in pre-clinical models are summarized.
Rapid Identification of Potential Drugs for Diabetic Nephropathy Using Whole-Genome Expression Profiles of Glomeruli
P Piperlongumine, 15d-PGJ2, vorinostat, and trichostatin A were predicted to be the most promising potential drugs for DN, acting as NF-κB inhibitors, histone deacetylase inhibitors, HDACIs, PI3K pathway inhibitors, or PPARγ agonists, respectively.
Expression of the Components of the Renin-Angiotensin System in Oncological Diseases
Literature data show promising pharmacological correction epigenetic modification of chromatin in the treatment of cancer and the possible role of epigenetic mechanisms in these processes.
Transcription Factors and Epigenetic Modulation: Its Therapeutic Implication in Chronic Kidney Disease
The current data regarding the role of epigenetic modulation in chronic kidney disease (CKD) and kidney fibrosis, including DNA methylation and histone modification are reviewed.
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Angiotensin II can modulate epigenetic regulation in podocytes and ARB inhibits these actions in part via KLF4 in proteinuric kidney diseases, providing a new concept that renin-angiotens in system blockade can exert therapeutic effects through epigenetic modulation of the kidney gene expression.
Recent Developments in Epigenetics of Acute and Chronic Kidney Diseases
Current knowledge on the role of epigenetic mechanisms (primarily DNA me and histone modifications) in acute and chronic kidney diseases, and their translational potential to identify much needed new therapies are discussed.
Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles


Systems approach identifies HIPK2 as a critical regulator of kidney fibrosis
Knockout of HIPK2 improved renal function and attenuated proteinuria and kidney fibrosis in Tg26 mice, as well as in other murine models of kidney Fibrosis, concluding that HIPK 2 is a potential target for anti-fibrosis therapy.
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
It is suggested that pharmacological HDAC inhibition may induce antifibrotic activity by inactivation of renal interstitial fibroblasts and inhibition of renal tubular cell death and STAT3 may mediate those actions of HDACs.
ARB protects podocytes from HIV-1 nephropathy independently of podocyte AT1.
Systemic AT1 inhibition with AT1 blocker (ARB) significantly attenuated proteinuria and glomerulosclerosis in HIV-1 mice, indicating that the protective effect of ARB is mediated through its receptors on cells other than podocytes, such as efferent arteriolar smooth muscle cells.
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin
It is reported here that TBP-2 expression is reduced in human primary breast and colon tumors compared with adjacent tissue, and this results support a model in which the expression of a subset of genes is repressed in transformed cells, leading to a block in differentiation, and culture of transformed cells with SAHA causes re-expression of these genes, leads to induction of growth arrest, differentiate, and/or apoptosis.
Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease
A systematic review and meta-analysis of the effects of ARBs on urinary protein excretion in patients with nephropathy compared with placebo and other antihypertensive agents and their combinations showed that ARBs delay progression of proteinuria over the short (1 to 4 months) and longer (5 to 12 months) terms.
Inhibition of renin activity slows down the progression of HIV-associated nephropathy.
In conclusion, inhibition of renin activity has a potential to slow down the progression of HIVAN and should be considered as a second line treatment for HIVAN.
Angiotensin receptor antagonists and increased risk of cancer. Further evidence against.
  • G. Mancia
  • Medicine, Biology
    Journal of hypertension
  • 2011
Results and meta-analyses were published in which the incidence and risk of cancer was found to be similar for several angiotensin receptor antagonists and other antihypertensive drugs confining the risk of carcinogenity associated with their continuing use to an unlikely possibility.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
Whether captopril has kidney-protecting properties independent of its effect on blood pressure in diabetic nephropathy is determined.
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
Captopril protects against deterioration in renal function in insulin-dependent diabetic nephropathy and is significantly more effective than blood-pressure control alone.
Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers
The X2K approach can advance the understanding of cell signaling and unravel drugs mechanisms of action by integrating chromatin immuno-precipitation data, protein-protein interactions and kinase-substrate phosphorylation reactions, and can better identify regulatory mechanisms upstream of genome-wide differences in gene expression.